Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
Did you mean: (tetrabenazine)?
(deutetrabenazine)
72 results
  • Tardive Dyskinesia: New Treatments Available. [Journal Article]
  • JPJ Psychosoc Nurs Ment Health Serv 2019 May 01; 57(5):11-14
  • Limandri BJ
  • Tardive dyskinesia (TD), the choreoathetoid movements of fingers, arms, legs, and trunk and irregular stereotypical movements of the mouth, face, and tongue, has been the scourge of antipsychotic med…
  • Overcoming barriers to effective management of tardive dyskinesia. [Review]
  • NDNeuropsychiatr Dis Treat 2019; 15:785-794
  • Caroff SN
  • Tardive dyskinesia (TD) is a heterogeneous syndrome of involuntary hyperkinetic movements that is often persistent and occurs belatedly during treatment with antipsychotics. Recent approval of two do…
  • Real-World Experience With VMAT2 Inhibitors. [Journal Article]
  • CNClin Neuropharmacol 2019 Mar/Apr; 42(2):37-41
  • Niemann N, Jankovic J
  • CONCLUSIONS: The VMAT2 inhibitors are effective and safe in a range of hyperkinetic movement disorders but are not readily accessible by patients in the United States for indications not approved by the Food and Drug Administration.
  • 46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study. [Journal Article]
  • CSCNS Spectr 2019; 24(1):201
  • Fernandez HH, Stamler D, … Anderson KE
  • CONCLUSIONS: These results confirm the safety outcomes seen in the ARM-TD and AIM-TD parent studies, demonstrating that deutetrabenazine is well tolerated for long-term use in TD patients.Presented at: American Academy of Neurology Annual Meeting; April 21-27, 2018, Los Angeles, California,USAFunding Acknowledgements: Funding: This study was supported by Teva Pharmaceuticals, Petach Tikva, Israel.
  • 35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia. [Journal Article]
  • CSCNS Spectr 2019; 24(1):193-194
  • Anderson KE, Stamler D, … Fernandez HH
  • CONCLUSIONS: Patients treated with DTB showed improvements in abnormal movements, as measured by site-rated AIMS, CGIC, and PGIC scores, which may be used in real-world clinical practice settings. These results corroborate the previously reported efficacy of DTB as observed in the 12-week, double-blind ARM-TD and AIM-TD trials, in which central raters were used to evaluate AIMS scores.Presented at: American Psychiatric Association Annual Meeting; May 5-9, 2018, New York, New York, USAFunding Acknowledgements: Funding: This study was supported by Teva Pharmaceuticals, Petach Tikva, Israel.
  • New directions in therapeutics for Huntington disease. [Review]
  • FNFuture Neurol 2018; 13(2):101-121
  • Potkin KT, Potkin SG
  • Huntington disease (HD) is an autosomal dominantly inherited neurodegenerative disease that affects motor, cognitive and psychiatric functions, and ultimately leads to death. The pathology of the dis…
New Search Next